Subscribe To

Price Alert Latest News Economic Calendar News

GANX / Gain Therapeutics to Participate at Cantor Fitzgerald Global Healthcare Conference 2023

BETHESDA, Md., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (the “Company”), a biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that the Company's Chief Executive Officer, Matthias Alder, will participate in a fireside chat and host one-on-one meetings at Cantor Fitzgerald Global Healthcare Conference taking place in New York, NY, September 26-28, 2023. Read More

Demo Live Account See Partner Details

Content Topics

Gain

Therapeutics

Participate

Cantor

Fitzgerald

Global

Healthcare

Conference

Stock

GANX

Posted: Sep 25 2023, 16:05

Author Name: GlobeNewsWire

GANX News

By InvestorPlace
October 4, 2023

Why Is Gain Therapeutics (GANX) Stock Moving Today?

Gain Therapeutics (NASDAQ: GANX ) stock is on the move Wednesday as investors react to updated clinical trial news from the company. According to a p

By GlobeNewsWire
September 25, 2023

Gain Therapeutics to Participate at Cantor Fitzgerald Global Healthcare Conference 2023

BETHESDA, Md., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (the “Company”), a biotechnology company leading the disc

By Zacks Investment Research
August 10, 2023

Gain Therapeutics, Inc. (GANX) Reports Q2 Loss, Misses Revenue Estimates

Gain Therapeutics, Inc. (GANX) came out with a quarterly loss of $0.62 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares

By Zacks Investment Research
May 12, 2023

Gain Therapeutics, Inc. (GANX) Reports Q1 Loss, Tops Revenue Estimates

Gain Therapeutics, Inc. (GANX) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares

By GlobeNewsWire
March 29, 2023

Gain Therapeutics to Present Positive Preclinical Data on its GBA1 Program at the AD/PD 2023 Meeting

Study results support the disease-modifying potential of structurally targeted allosteric regulators of GCase for the treatment of Alzheimer's disease

By Zacks Investment Research
May 16, 2022

Gain Therapeutics, Inc. (GANX) Reports Q1 Loss, Misses Revenue Estimates

Gain Therapeutics, Inc. (GANX) delivered earnings and revenue surprises of 17.65% and 25%, respectively, for the quarter ended March 2022. Do the numb

By Benzinga
March 15, 2022

Gain Therapeutics Posts Encouraging Preclinical Data From Parkinson's, Alzheimer's Programs

Gain Therapeutics Inc (NASDAQ: GANX) has presented new preclinical data from its Parkinson's and Alzheimer's Disease programs. These results were

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.